Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling

British Journal of Pharmacology

Volumn 171, Issue 23, 2014, Pages 5387-5406

  Balenga, N A ^a,f   Martinez Pinilla E ^b   Kargl, J ^a,g   Schroder R ^c   Peinhaupt, M ^a   Platzer, W ^a   Balint Z ^d   Zamarbide, M ^b   Dopeso Reyes, I G ^b   Ricobaraza, A ^b   Perez Ortiz J M ^b   Kostenis, E ^c   Waldhoer, M ^a,h   Heinemann, A ^a   Franco, R ^b,e  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF BONN   (Germany)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g USA   (United States)

^h NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPR55 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

HEK293 CELL LINE; HUMAN; METABOLISM; SERUM RESPONSIVE ELEMENT; SIGNAL TRANSDUCTION;

HEK293 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; SERUM RESPONSE ELEMENT; SIGNAL TRANSDUCTION;

EID: 84928502303     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12850     Document Type: Article

References (75)

1. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Andradas C, Caffarel MM, Perez-Gomez E, Salazar M, Lorente M, Velasco G, et al. (2011). The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30: 245-252.
4. Atwood BK, Straiker A, Mackie K, (2012). CB(2): therapeutic target-in-waiting. Prog Neuropsychopharmacol Biol Psychiatry 38: 16-20.
5. Balenga NA, Aflaki E, Kargl J, Platzer W, Schroder R, Blattermann S, et al. (2011a). GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 21: 1452-1469.
6. Balenga NA, Henstridge CM, Kargl J, Waldhoer M, (2011b). Pharmacology, signaling and physiological relevance of the G protein-coupled receptor 55. Adv Pharmacol 62: 251-277.
7. Basu S, Ray A, Dittel BN, (2013). Cannabinoid receptor 2 (CB2) plays a role in the generation of germinal center and memory B cells, but not in the production of antigen-specific IgG and IgM, in response to T-dependent antigens. PLoS ONE 8: e67587.
8. Blattermann S, Peters L, Ottersbach PA, Bock A, Konya V, Weaver CD, et al. (2012). A biased ligand for OXE-R uncouples Galpha and Gbetagamma signaling within a heterotrimer. Nat Chem Biol 8: 631-638.
9. Brown AJ, Robin Hiley C, (2009). Is GPR55 an anandamide receptor? Vitam Horm 81: 111-137.
10. Brown AJ, Daniels DA, Kassim M, Brown S, Haslam CP, Terrell VR, et al. (2011). Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther 337: 236-246.
11. Buchwalter G, Gross C, Wasylyk B, (2004). Ets ternary complex transcription factors. Gene 324: 1-14.
12. Callen L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cortes A, Mallol J, et al. (2012). Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem 287: 20851-20865.
13. Cheng Y, Hitchcock SA, (2007). Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs 16: 951-965.
14. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48: 443-450.
15. Ferre S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, et al. (2009). Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5: 131-134.
16. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB, (2003). The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63: 1256-1272.
17. Guindon J, Hohmann AG, (2009). The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 8: 403-421.
18. Guindon J, Hohmann AG, (2011). The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 163: 1447-1463.
19. Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ, (2009). The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23: 183-193.
20. Henstridge CM, Balenga NA, Schroder R, Kargl JK, Platzer W, Martini L, et al. (2010). GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160: 604-614.
21. Hiley CR, Kaup SS, (2007). GPR55 and the vascular receptors for cannabinoids. Br J Pharmacol 152: 559-561.
22. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, et al. (2002). Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 277: 18091-18097.
23. Howlett AC, (2005). Cannabinoid receptor signaling. Handb Exp Pharmacol 168: 53-79.
24. Hu G, Ren G, Shi Y, (2011). The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene 30: 139-141.
25. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152: 825-831.
26. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, et al. (2009). Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284: 29817-29827.
27. Kargl J, Balenga N, Parzmair GP, Brown AJ, Heinemann A, Waldhoer M, (2012). The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J Biol Chem 287: 44234-44248.
28. Kargl J, Brown AJ, Andersen L, Dorn G, Schicho R, Waldhoer M, et al. (2013). A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther 346: 54-66.
29. Kuwahara K, Barrientos T, Pipes GC, Li S, Olson EN, (2005). Muscle-specific signaling mechanism that links actin dynamics to serum response factor. Mol Cell Biol 25: 3173-3181.
30. Lagane B, Ballet S, Planchenault T, Balabanian K, Le Poul E, Blanpain C, et al. (2005). Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis. Mol Pharmacol 67: 1966-1976.
31. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. (2001). Initial sequencing and analysis of the human genome. Nature 409: 860-921.
32. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K, (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105: 2699-2704.
33. Martini L, Waldhoer M, Pusch M, Kharazia V, Fong J, Lee JH, et al. (2007). Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. FASEB J 21: 802-811.
34. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
35. Miano JM, Long X, Fujiwara K, (2007). Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol 292: C70-C81.
36. Miralles F, Posern G, Zaromytidou AI, Treisman R, (2003). Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 113: 329-342.
37. Napetschnig J, Wu H, (2013). Molecular basis of NF-kappaB signaling. Annu Rev Biophys 42: 443-468.
38. Nevalainen T, Irving AJ, (2010). GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr Top Med Chem 10: 799-813.
39. Obara Y, Ueno S, Yanagihata Y, Nakahata N, (2011). Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells. PLoS ONE 6: e24284.
40. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T, (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362: 928-934.
41. Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T, (2009). 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 145: 13-20.
42. Oka S, Kimura S, Toshida T, Ota R, Yamashita A, Sugiura T, (2010). Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 147: 671-678.
43. Pacher P, Kunos G, (2013). Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J 280: 1918-1943.
44. Pacher P, Batkai S, Kunos G, (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
45. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
46. Perez-Gomez E, Andradas C, Flores JM, Quintanilla M, Paramio JM, Guzman M, et al. (2013). The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene 32: 2534-2542.
47. Pertwee RG, (2007). GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 152: 984-986.
48. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. (2010). International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 62: 588-631.
49. Peters MF, Vaillancourt F, Heroux M, Valiquette M, Scott CW, (2010). Comparing label-free biosensors for pharmacological screening with cell-based functional assays. Assay Drug Dev Technol 8: 219-227.
50. Petitet F, Donlan M, Michel A, (2006). GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem Biol Drug Des 67: 252-253.
51. Pineiro R, Maffucci T, Falasca M, (2011). The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30: 142-152.
52. Ramirez SH, Reichenbach NL, Fan S, Rom S, Merkel SF, Wang X, et al. (2013). Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists. J Leukoc Biol 93: 801-810.
53. Renner U, Zeug A, Woehler A, Niebert M, Dityatev A, Dityateva G, et al. (2012). Heterodimerization of serotonin receptors 5-HT1A and 5-HT7 differentially regulates receptor signalling and trafficking. J Cell Sci 125 (Pt 10): 2486-2499.
54. Rivero-Muller A, Chou YY, Ji I, Lajic S, Hanyaloglu AC, Jonas K, et al. (2010). Rescue of defective G protein-coupled receptor function in vivo by intermolecular cooperation. Proc Natl Acad Sci U S A 107: 2319-2324.
55. Robbs BK, Lucena PI, Viola JP, (2013). The transcription factor NFAT1 induces apoptosis through cooperation with Ras/Raf/MEK/ERK pathway and upregulation of TNF-alpha expression. Biochim Biophys Acta 1833: 2016-2028.
56. Rocheville M, Martin J, Jerman J, Kostenis E, (2013). Mining the potential of label-free biosensors for seven-transmembrane receptor drug discovery. Prog Mol Biol Transl Sci 115: 123-142.
57. Rozenfeld R, Devi LA, (2011). Exploring a role for heteromerization in GPCR signalling specificity. Biochem J 433: 11-18.
58. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
59. Schroder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, et al. (2010). Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 28: 943-949.
60. Scott CW, Peters MF, (2010). Label-free whole-cell assays: expanding the scope of GPCR screening. Drug Discov Today 15: 704-716.
61. Sedej M, Schroder R, Bell K, Platzer W, Vukoja A, Kostenis E, et al. (2012). D-type prostanoid receptor enhances the signaling of chemoattractant receptor-homologous molecule expressed on T(H)2 cells. J Allergy Clin Immunol 129: 492-500, 500 e491-499.
62. Showalter VM, Compton DR, Martin BR, Abood ME, (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989-999.
63. Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, et al. (2008). The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139: 225-236.
64. Stefos GC, Soppa U, Dierssen M, Becker W, (2013). NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect. PLoS ONE 8: e67470.
65. Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, et al. (1999). Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem 274: 2794-2801.
66. Tadagaki K, Jockers R, Kamal M, (2012). History and biological significance of GPCR heteromerization in the neuroendocrine system. Neuroendocrinology 95: 223-231.
67. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH, (1998). Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285: 285-292.
68. Vickers ER, Kasza A, Kurnaz IA, Seifert A, Zeef LA, O'Donnell A, et al. (2004). Ternary complex factor-serum response factor complex-regulated gene activity is required for cellular proliferation and inhibition of apoptotic cell death. Mol Cell Biol 24: 10340-10351.
69. Wager-Miller J, Westenbroek R, Mackie K, (2002). Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids 121: 83-89.
70. Waldeck-Weiermair M, Zoratti C, Osibow K, Balenga N, Goessnitzer E, Waldhoer M, et al. (2008). Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121 (Pt 10): 1704-1717.
71. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, et al. (2005). A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A 102: 9050-9055.
72. Yang SH, Shore P, Willingham N, Lakey JH, Sharrocks AD, (1999). The mechanism of phosphorylation-inducible activation of the ETS-domain transcription factor Elk-1. EMBO J 18: 5666-5674.
73. Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV, et al. (2008). In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 153: 390-401.
74. Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, et al. (2009). Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 328: 141-151.
75. Zaslavsky A, Chou ST, Schadler K, Lieberman A, Pimkin M, Kim YJ, et al. (2013). The calcineurin-NFAT pathway negatively regulates megakaryopoiesis. Blood 121: 3205-3215.